



(11) **EP 3 774 775 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**
- (48) Corrigendum issued on:  
**15.11.2023 Bulletin 2023/46**
- (45) Date of publication and mention of the grant of the patent:  
**11.10.2023 Bulletin 2023/41**
- (21) Application number: **19725404.8**
- (22) Date of filing: **11.04.2019**
- (51) International Patent Classification (IPC):  
**C07D 401/14<sup>(2006.01)</sup> C07D 405/14<sup>(2006.01)</sup>**  
**C07D 403/14<sup>(2006.01)</sup> A61P 31/18<sup>(2006.01)</sup>**  
**A61K 31/517<sup>(2006.01)</sup>**
- (52) Cooperative Patent Classification (CPC):  
**C07D 403/14; A61P 31/18; C07D 401/14;**  
**C07D 405/14**
- (86) International application number:  
**PCT/IB2019/052990**
- (87) International publication number:  
**WO 2019/198024 (17.10.2019 Gazette 2019/42)**

(54) **4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION**

4-OXO-3,4-DIHYDROCHINAZOLIN-VERBINDUNGEN ALS INHIBITOREN DER REPLIKATION DES MENSCHLICHEN IMMUNDEFIZIENZVIRUS

COMPOSÉS DE 4-OXO-3,4-DIHYDROQUINAZOLINE UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE

- (84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (30) Priority: **11.04.2018 US 201862655881 P**  
**26.06.2018 US 201862689995 P**  
**18.09.2018 US 201862732741 P**  
**25.10.2018 US 201862750336 P**
- (43) Date of publication of application:  
**17.02.2021 Bulletin 2021/07**
- (73) Proprietor: **VIIV Healthcare UK (No.5) Limited**  
**Stevenage SG1 2NY (GB)**
- (72) Inventors:  
• **BELEMA, Makonen**  
**Wallingford, Connecticut 06492 (US)**  
• **BENDER, John A.**  
**Wallingford, Connecticut 06492 (US)**  
• **FRENNESSON, David B.**  
**Wallingford, Connecticut 06492 (US)**
- **GILLIS, Eric P**  
**Branford, Connecticut 06405 (US)**
  - **IWUAGWU, Christiana**  
**Branford, Connecticut 06405 (US)**
  - **KADOW, John F**  
**Branford, Connecticut 06405 (US)**
  - **NAIDU, B. Narasimhulu**  
**Branford, Connecticut 06405 (US)**
  - **PARCELLA, Kyle E.**  
**Branford, Connecticut 06405 (US)**
  - **PEESE, Kevin M.**  
**Branford, Connecticut 06405 (US)**
  - **RAJAMANI, Ramkumar**  
**Wallingford, Connecticut 06492 (US)**
  - **SAULNIER, Mark G.**  
**Wallingford, Connecticut 06492 (US)**
  - **WANG, Alan Xiangdong**  
**Wallingford, Connecticut 06492 (US)**
  - **BOWSHER, Michael S**  
**Branford, CT 06405 (US)**
  - **PATEL, Manoj**  
**Branford, CT 06405 (US)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 774 775 B8**

(74) Representative: **Billson, Siân Catherine et al**  
**GlaxoSmithKline**  
**Global Patents (CN925.1)**  
**980 Great West Road**  
**Brentford, Middlesex TW8 9GS (GB)**

(56) References cited:

<b>WO-A1-2013/006738</b>	<b>WO-A1-2014/110297</b>
<b>WO-A1-2014/110298</b>	<b>WO-A1-2016/033243</b>
<b>WO-A1-2018/203235</b>	<b>WO-A1-2020/084480</b>
<b>WO-A1-2020/084492</b>	<b>WO-A2-2014/134566</b>